EXACT Sciences Corporation  

(Public, NASDAQ:EXAS)   Watch this stock  
Find more results for EXAS
22.49
+1.16 (5.44%)
Mar 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 21.33 - 22.62
52 week 10.69 - 29.97
Open 21.34
Vol / Avg. 1.93M/2.18M
Mkt cap 1.99B
P/E     -
Div/yield     -
EPS -1.23
Shares 88.67M
Beta 1.21
Inst. own 95%
Apr 29, 2015
Q1 2015 Exact Sciences Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 10, 2015
Exact Sciences Corp at ROTH Conference - Webcast
Mar 3, 2015
Exact Sciences Corp at Cowen Health Care Conference
Feb 24, 2015
Q4 2014 Exact Sciences Corp Earnings Call
Feb 24, 2015
Q4 2014 Exact Sciences Corp Earnings Release
Feb 12, 2015
Exact Sciences Corp at Leerink Global Healthcare Conference
Jan 14, 2015
Exact Sciences Corp at JPMorgan Healthcare Conference-Q&A session
Jan 14, 2015
Exact Sciences Corp at JPMorgan Healthcare Conference
Jan 13, 2015
Exact Sciences Corp at JPMorgan Healthcare Conference Q&A session
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -2157.18% -5564.40%
Operating margin -2166.42% -5591.71%
EBITD margin - -5385.37%
Return on average assets -47.64% -43.67%
Return on average equity -51.63% -47.16%
Employees 236 -
CDP Score - -

Address

441 Charmany Dr
MADISON, WI 53719-1234
United States - Map
+1-608-2845700 (Phone)
+1-608-2845701 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company has developed an accurate, non-invasive, screening test for the early detection of colorectal pre-cancer and cancer. The Company�s Cologuard test is a non-invasive, stool-based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers, which in published studies have been shown to be associated with colorectal cancer. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test (FIT). Its Cologuard test is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer.

Officers and directors

Kevin T. Conroy Chairman of the Board
Age: 48
Bio & Compensation  - Reuters
William J. Megan Principal Financial Officer, Senior Vice President - Finance
Age: 57
Bio & Compensation  - Reuters
Maneesh K. Arora Chief Operating Officer, Senior Vice President
Age: 45
Bio & Compensation  - Reuters
Graham P. Lidgard Ph.D. Senior Vice President, Chief Scientific Officer
Age: 65
Bio & Compensation  - Reuters
David A. Thompson Lead Independent Director
Age: 72
Bio & Compensation  - Reuters
Michael S. Wyzga Director
Age: 59
Bio & Compensation  - Reuters
Thomas D. Carey Independent Director
Age: 52
Bio & Compensation  - Reuters
Sally W. Crawford Independent Director
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Daniel J. Levangie Independent Director
Age: 63
Bio & Compensation  - Reuters